Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer

Kazumasa Miki, Masao Ichinose, Koichi B. Ishikawa, Naohisa Yahagi, Masashi Matsushima, Nobuyuki Kakei, Shinko Tsukada, Masahiro Kido, Satoshi Ishihama, Yasuhito Shimizu, Takehisa Suzuki, Kiyoshi Kurokawa

Research output: Contribution to journalArticle

126 Citations (Scopus)

Abstract

A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive. Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this method. Out of 875 subjects (18.8%) with a serum pepsinogen I level of less than 50 μg/liter and a pepsinogen I II ratio of less than 3.0, 676 subjects (14.5%) were selected for further investigation by endoscopy. This led to the detection of four subjects (0.086%) with gastric cancer (three in an early stage) and four subjects with adenoma. The cancer detection rate of this new screening method was comparable, and in some respects superior, to that of the traditional barium X-ray screening. Since the incidence of test-positive subjects was as low as 10% amongst subjects aged less than 40, this screening method appears to be especially useful for screening of younger generations. The new method is less expensive than the traditional barium X-ray and subjects experience little discomfort. Further, many serum samples can be quickly measured simultaneously. The results of this study have indicated that serum pepsinogen screening provides a valuable method for detecting gastric cancers.

Original languageEnglish
Pages (from-to)1086-1090
Number of pages5
JournalJapanese Journal of Cancer Research
Volume84
Issue number10
Publication statusPublished - 1993 Oct
Externally publishedYes

Fingerprint

Pepsinogen C
Pepsinogen A
Mass Screening
Stomach Neoplasms
Serum
Atrophic Gastritis
Barium
X-Rays
Adenoma
Endoscopy
Mucous Membrane
Incidence

Keywords

  • Gastric cancer
  • Mass screening
  • Pepsinogen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Miki, K., Ichinose, M., Ishikawa, K. B., Yahagi, N., Matsushima, M., Kakei, N., ... Kurokawa, K. (1993). Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. Japanese Journal of Cancer Research, 84(10), 1086-1090.

Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. / Miki, Kazumasa; Ichinose, Masao; Ishikawa, Koichi B.; Yahagi, Naohisa; Matsushima, Masashi; Kakei, Nobuyuki; Tsukada, Shinko; Kido, Masahiro; Ishihama, Satoshi; Shimizu, Yasuhito; Suzuki, Takehisa; Kurokawa, Kiyoshi.

In: Japanese Journal of Cancer Research, Vol. 84, No. 10, 10.1993, p. 1086-1090.

Research output: Contribution to journalArticle

Miki, K, Ichinose, M, Ishikawa, KB, Yahagi, N, Matsushima, M, Kakei, N, Tsukada, S, Kido, M, Ishihama, S, Shimizu, Y, Suzuki, T & Kurokawa, K 1993, 'Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer', Japanese Journal of Cancer Research, vol. 84, no. 10, pp. 1086-1090.
Miki, Kazumasa ; Ichinose, Masao ; Ishikawa, Koichi B. ; Yahagi, Naohisa ; Matsushima, Masashi ; Kakei, Nobuyuki ; Tsukada, Shinko ; Kido, Masahiro ; Ishihama, Satoshi ; Shimizu, Yasuhito ; Suzuki, Takehisa ; Kurokawa, Kiyoshi. / Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer. In: Japanese Journal of Cancer Research. 1993 ; Vol. 84, No. 10. pp. 1086-1090.
@article{9e9d75e45ee14861943914dec0ca556b,
title = "Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer",
abstract = "A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive. Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this method. Out of 875 subjects (18.8{\%}) with a serum pepsinogen I level of less than 50 μg/liter and a pepsinogen I II ratio of less than 3.0, 676 subjects (14.5{\%}) were selected for further investigation by endoscopy. This led to the detection of four subjects (0.086{\%}) with gastric cancer (three in an early stage) and four subjects with adenoma. The cancer detection rate of this new screening method was comparable, and in some respects superior, to that of the traditional barium X-ray screening. Since the incidence of test-positive subjects was as low as 10{\%} amongst subjects aged less than 40, this screening method appears to be especially useful for screening of younger generations. The new method is less expensive than the traditional barium X-ray and subjects experience little discomfort. Further, many serum samples can be quickly measured simultaneously. The results of this study have indicated that serum pepsinogen screening provides a valuable method for detecting gastric cancers.",
keywords = "Gastric cancer, Mass screening, Pepsinogen",
author = "Kazumasa Miki and Masao Ichinose and Ishikawa, {Koichi B.} and Naohisa Yahagi and Masashi Matsushima and Nobuyuki Kakei and Shinko Tsukada and Masahiro Kido and Satoshi Ishihama and Yasuhito Shimizu and Takehisa Suzuki and Kiyoshi Kurokawa",
year = "1993",
month = "10",
language = "English",
volume = "84",
pages = "1086--1090",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer

AU - Miki, Kazumasa

AU - Ichinose, Masao

AU - Ishikawa, Koichi B.

AU - Yahagi, Naohisa

AU - Matsushima, Masashi

AU - Kakei, Nobuyuki

AU - Tsukada, Shinko

AU - Kido, Masahiro

AU - Ishihama, Satoshi

AU - Shimizu, Yasuhito

AU - Suzuki, Takehisa

AU - Kurokawa, Kiyoshi

PY - 1993/10

Y1 - 1993/10

N2 - A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive. Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this method. Out of 875 subjects (18.8%) with a serum pepsinogen I level of less than 50 μg/liter and a pepsinogen I II ratio of less than 3.0, 676 subjects (14.5%) were selected for further investigation by endoscopy. This led to the detection of four subjects (0.086%) with gastric cancer (three in an early stage) and four subjects with adenoma. The cancer detection rate of this new screening method was comparable, and in some respects superior, to that of the traditional barium X-ray screening. Since the incidence of test-positive subjects was as low as 10% amongst subjects aged less than 40, this screening method appears to be especially useful for screening of younger generations. The new method is less expensive than the traditional barium X-ray and subjects experience little discomfort. Further, many serum samples can be quickly measured simultaneously. The results of this study have indicated that serum pepsinogen screening provides a valuable method for detecting gastric cancers.

AB - A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive. Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer. In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this method. Out of 875 subjects (18.8%) with a serum pepsinogen I level of less than 50 μg/liter and a pepsinogen I II ratio of less than 3.0, 676 subjects (14.5%) were selected for further investigation by endoscopy. This led to the detection of four subjects (0.086%) with gastric cancer (three in an early stage) and four subjects with adenoma. The cancer detection rate of this new screening method was comparable, and in some respects superior, to that of the traditional barium X-ray screening. Since the incidence of test-positive subjects was as low as 10% amongst subjects aged less than 40, this screening method appears to be especially useful for screening of younger generations. The new method is less expensive than the traditional barium X-ray and subjects experience little discomfort. Further, many serum samples can be quickly measured simultaneously. The results of this study have indicated that serum pepsinogen screening provides a valuable method for detecting gastric cancers.

KW - Gastric cancer

KW - Mass screening

KW - Pepsinogen

UR - http://www.scopus.com/inward/record.url?scp=0027371774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027371774&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 1086

EP - 1090

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 10

ER -